Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

Br J Haematol. 2008 Apr;141(1):80-3. doi: 10.1111/j.1365-2141.2008.07010.x.

Abstract

Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced-intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post-transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Contraindications
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukocyte Count
  • Middle Aged
  • Platelet Count
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / pathology
  • Primary Myelofibrosis / therapy*
  • Prognosis
  • Retrospective Studies
  • Splenomegaly / blood
  • Splenomegaly / etiology*
  • Splenomegaly / pathology
  • Transplantation Conditioning / methods
  • Treatment Outcome